Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.44 |
| ▸ | PIK3CD | O00329 | 5/20 | 0.42 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.40 |
| ▸ | CYP8B1 | Q9UNU6 | 1/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.39 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.39 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL924135 | 1.00 | GPR119 (0.44) | GPR119PIK3CDUSP30CYP8B1PIK3CA | |
| SCHEMBL924133 | 1.00 | GPR119 (0.44) | GPR119PIK3CDUSP30CYP8B1PIK3CA | |
| SCHEMBL2537062 | 0.79 | JAK1 (0.40) | MAP4K4 | |
| SCHEMBL2537065 | 0.79 | JAK1 (0.40) | MAP4K4 | |
| SCHEMBL3374285 | 0.79 | JAK1 (0.40) | MAP4K4 | |
| SCHEMBL2537063 | 0.79 | JAK1 (0.40) | MAP4K4 | |
| SCHEMBL3374280 | 0.79 | JAK1 (0.40) | MAP4K4 | |
| SCHEMBL634126 | 0.77 | KCNH2 (0.44) | GPR119PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL634125 | 0.77 | KCNH2 (0.44) | GPR119PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL2252681 | 0.77 | KCNH2 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9505750-B2 | 5-aminocyclylmethyl-oxazolidin-2-one derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2016-11-29 | — | — | US | disclosed |
| US-20110003789-A1 | 5-AMINOCYCLYLMETHYL-OXAZOLIDIN-2-ONE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2011-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003789-A1 | 5-AMINOCYCLYLMETHYL-OXAZOLIDIN-2-ONE DERIVATIVES | CNKSR1, KCNH1, CBR3 | GPR119 2186/4885PIK3CD 3587/4885USP30 3264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.